Aptose Biosciences Advances AML Triplet Therapy
Company Announcements

Aptose Biosciences Advances AML Triplet Therapy

Story Highlights

Aptose Biosciences (TSE:APS) has released an update.

Aptose Biosciences is advancing the development of its promising drug tuspetinib as part of a triplet therapy for acute myeloid leukemia (AML), showing strong clinical activity and a unique safety profile. The company has secured a $10 million loan from Hanmi Pharmaceutical to support the clinical development of tuspetinib, with plans for a new co-development collaboration. Tuspetinib has demonstrated potential to address unmet needs in AML treatment by avoiding common toxicities associated with other therapies.

For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAptose Biosciences Reports Q3 2024 Financial Highlights
Christine BrownAPTO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App